Position in CELC
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$7,594,156
-$18,726,870 QoQ
Shares Held
72,588
-68.5% QoQ
Ownership
0.148%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#75
of 274 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CELC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Candriam S.C.A. holds $2,107,868,027 across 75 Biotechnology names. CELC ranks #66 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
195,674 | $122,010,565 | |
| 2 | RVMD |
Revolution Medicines, Inc.
|
556,392 | $104,201,093 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
199,505 | $99,100,118 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
314,512 | $94,677,547 | |
| 5 | ONC |
BeOne Medicines Ltd.
|
289,735 | $82,565,782 | |
| 6 | COGT |
Cogent Biosciences, Inc.
|
2,088,369 | $80,819,880 | |
| 7 | ARGX |
Argenx SE
|
80,120 | $74,332,932 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
1,990,510 | $70,444,148 |
All Filings in CELC
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7,594,156 | 72,588 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $26,321,026 | 230,603 | Shares | Sole | 2026-04-30 | |
| 2025-12-31 | $47,513,143 | 476,370 | Shares | Sole | 2026-04-30 | |
| 2025-09-30 | $19,311,645 | 390,924 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $3,518,739 | 263,576 | Shares | Sole | 2025-08-08 | |
| 2025-03-31 | $2,664,894 | 263,590 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $3,450,392 | 263,590 | Shares | Sole | 2025-02-07 | |
| No filing history on record for this holder in this stock. | ||||||